US 12,006,352 B2
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
Judith Baumeister, Mechelen (BE); Marie-Paule Lucienne Armanda Bouche, Gentbrugge (BE); Carlo Boutton, Wielsbeke (BE); Marie-Ange Buyse, Merelbeke (BE); Veerle Snoeck, Zingem (BE); Stephanie Staelens, Wevelgem (BE); Bruno Dombrecht, Heusden (BE); Peter Schotte, De Pinte (BE); Cedric Jozef Neotere Ververken, Merelbeke (BE); Gerald Beste, Ghent (BE); Guy Hermans, Merelbeke (BE); Soren Steffensen, Etterbeek (BE); Alexander Szyroki, Goldenstedt (DE); and Tinneke Denayer, De Pinte (BE)
Assigned to Ablynx N.V., Ghent-Zwijnaarde (BE); and Sanofi, Paris (FR)
Filed by Ablynx N.V., Ghent-Zwijnaarde (BE); and Sanofi, Paris (FR)
Filed on Mar. 19, 2020, as Appl. No. 16/823,412.
Application 16/823,412 is a continuation of application No. 14/128,681, previously published as PCT/EP2012/062251, filed on Jun. 25, 2012.
Application 14/128,681 is a continuation in part of application No. PCT/EP2012/061304, filed on Jun. 14, 2012.
Application 14/128,681 is a continuation in part of application No. 13/435,567, filed on Mar. 30, 2012, granted, now 8,703,135.
Application 14/128,681 is a continuation in part of application No. PCT/EP2011/067132, filed on Sep. 30, 2011.
Claims priority of provisional application 61/541,368, filed on Sep. 30, 2011.
Claims priority of provisional application 61/500,464, filed on Jun. 23, 2011.
Claims priority of provisional application 61/500,360, filed on Jun. 23, 2011.
Prior Publication US 2020/0325221 A1, Oct. 15, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/00 (2006.01); C07K 16/18 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); C07K 16/42 (2006.01); G01N 33/53 (2006.01); G01N 33/543 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/00 (2013.01) [C07K 16/18 (2013.01); A61K 39/39533 (2013.01); A61K 2039/505 (2013.01); C07K 16/28 (2013.01); C07K 16/2875 (2013.01); C07K 16/42 (2013.01); C07K 16/4283 (2013.01); C07K 2317/22 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/35 (2013.01); C07K 2317/567 (2013.01); C07K 2317/569 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/30 (2013.01); G01N 33/5306 (2013.01); G01N 33/54393 (2013.01); G01N 33/6854 (2013.01); G01N 33/6857 (2013.01)] 6 Claims
 
1. A polypeptide comprising a serum albumin binding immunoglobulin single variable domain (VH or VHH) at its C-terminal end, wherein the immunoglobulin single variable domain ends with the sequence VTVSS(X) n (SEQ ID NO: 34), in which n is 1 to 5, with each X being independently chosen from any amino acid, with the proviso that X is not cysteine (C); and wherein the immunoglobulin single variable domain:
(i) is not Alb-1; and
(ii) does not end with the sequence VTVSSA (SEQ ID NO: 90).